(MT Newswires) -- AstraZeneca (AZN) Chief Executive Officer Pascal Soriot's efforts to rejuvenate the pharmaceutical company's pipeline of treatments are paying off, with a bet on new cancer drugs. Astra recorded better-than-expected results for 2022 and forecast another good year for 2023. Soriot spoke to Bloomberg's Anna Edwards and Mark Cudmore in an exclusive interview.

Bloomberg videos